MAPK pathway activation is also known to downregulate the expression of type I IFN-α receptor-1 (IFNAR1), which mediates the effects of IFN-α, a cytokine used for the adjuvant treatment of high-risk melanoma [16–19]. Here, IFNA2 is linked to melanoma.